Bicocca Open Archive

Logo unimib boa
CECCON, MONICA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.680
AS - Asia 2.057
EU - Europa 1.933
SA - Sud America 311
Continente sconosciuto - Info sul continente non disponibili 227
AF - Africa 64
OC - Oceania 5
Totale 9.277
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.426
SG - Singapore 751
CN - Cina 444
IT - Italia 417
DE - Germania 347
VN - Vietnam 266
HK - Hong Kong 242
RU - Federazione Russa 234
BR - Brasile 216
CA - Canada 207
IE - Irlanda 193
SE - Svezia 192
GB - Regno Unito 141
UA - Ucraina 98
FR - Francia 84
IN - India 75
FI - Finlandia 52
AT - Austria 42
AR - Argentina 37
BD - Bangladesh 37
TR - Turchia 32
PL - Polonia 31
ID - Indonesia 28
IQ - Iraq 28
JP - Giappone 27
KR - Corea 24
ZA - Sudafrica 24
BE - Belgio 21
ES - Italia 21
PK - Pakistan 20
NL - Olanda 17
CO - Colombia 15
DK - Danimarca 14
MA - Marocco 14
MX - Messico 14
SA - Arabia Saudita 12
VE - Venezuela 11
CL - Cile 8
CW - ???statistics.table.value.countryCode.CW??? 8
PH - Filippine 8
UZ - Uzbekistan 8
EC - Ecuador 7
LT - Lituania 7
PY - Paraguay 7
JO - Giordania 6
KE - Kenya 6
PE - Perù 6
TN - Tunisia 6
AZ - Azerbaigian 5
HN - Honduras 5
IR - Iran 5
NP - Nepal 5
TH - Thailandia 5
AU - Australia 4
BG - Bulgaria 4
CR - Costa Rica 4
EE - Estonia 4
NI - Nicaragua 4
PR - Porto Rico 4
PS - Palestinian Territory 4
SV - El Salvador 4
BO - Bolivia 3
DZ - Algeria 3
KG - Kirghizistan 3
MY - Malesia 3
NG - Nigeria 3
AE - Emirati Arabi Uniti 2
AM - Armenia 2
CH - Svizzera 2
DO - Repubblica Dominicana 2
EU - Europa 2
HU - Ungheria 2
IL - Israele 2
JM - Giamaica 2
KZ - Kazakistan 2
MU - Mauritius 2
PA - Panama 2
SI - Slovenia 2
TT - Trinidad e Tobago 2
AO - Angola 1
BA - Bosnia-Erzegovina 1
BH - Bahrain 1
BM - Bermuda 1
BN - Brunei Darussalam 1
BS - Bahamas 1
EG - Egitto 1
ET - Etiopia 1
GE - Georgia 1
GP - Guadalupe 1
GT - Guatemala 1
HR - Croazia 1
LA - Repubblica Popolare Democratica del Laos 1
LK - Sri Lanka 1
LY - Libia 1
MD - Moldavia 1
MK - Macedonia 1
MM - Myanmar 1
MN - Mongolia 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
Totale 9.050
Salva come PNG Salva come JPEG
Città #
Ann Arbor 502
Ashburn 480
Singapore 403
San Jose 294
Hong Kong 240
Frankfurt am Main 223
Fairfield 207
Chandler 206
Woodbridge 206
Milan 204
Dublin 190
Houston 160
Wilmington 137
Toronto 118
Council Bluffs 113
New York 109
Dearborn 107
Jacksonville 91
Seattle 91
Los Angeles 90
Santa Clara 79
Chicago 78
Cambridge 74
Beijing 70
Ho Chi Minh City 70
Hanoi 63
Princeton 53
Nanjing 47
Dallas 45
The Dalles 43
Vienna 36
Munich 29
Hefei 28
Lauterbourg 28
São Paulo 28
Boardman 27
Shanghai 26
Altamura 24
Buffalo 24
Lawrence 23
Nanchang 22
Seoul 21
Washington 21
Montreal 20
Brussels 19
Phoenix 19
Warsaw 19
Brooklyn 18
Helsinki 18
Moscow 18
San Diego 18
Tokyo 18
Columbus 17
Jakarta 17
Da Nang 16
Denver 16
Orem 16
Rome 16
Lachine 15
Turku 15
Atlanta 14
Fremont 14
Newark 14
Guangzhou 13
Johannesburg 13
Rio de Janeiro 13
Göttingen 12
London 12
Chennai 11
North Bergen 10
Norwalk 10
Poplar 10
Trento 10
Baghdad 9
Falls Church 9
Haiphong 9
Hangzhou 9
Lahore 9
Lissone 9
Manchester 9
Ottawa 9
Philadelphia 9
Pune 9
Salt Lake City 9
Andover 8
Edmonton 8
Shenyang 8
Stockholm 8
Tianjin 8
Willemstad 8
Amsterdam 7
Brasília 7
Chengdu 7
Jiaxing 7
Lodz 7
San Francisco 7
Taizhou 7
Tashkent 7
Amman 6
Boston 6
Totale 5.796
Salva come PNG Salva come JPEG
Nome #
Lorlatinib treatment elicits multiple on- and off-target mechanisms of resistance in ALK-driven cancer 603
Long-term efficacy and safety of crizotinib in relapsed ALK positive lymphoma patients: clinical and biological correlates 479
Excess of NPM-ALK oncogenic signaling promotes cellular apoptosis and drug dependency 469
Three novel patients derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors 446
Synergistic activity of ALK and mTOR inhibitors for the treatment of NPM-ALK positive lymphoma 422
In vitro and in vivo identification of ABCB1 as an efflux transporter of bosutinib 386
Treatment efficacy and resistance mechanisms using the second-generation ALK inhibitor AP26113 in human NPM-ALK-positive anaplastic large cell lymphoma 377
Abstract 902: In vitro andin vivocharacterization of resistance to lorlatinib treatment in ALK mutated cancers 374
Mitochondrial Hyperactivation and Enhanced ROS Production are Involved in Toxicity Induced by Oncogenic Kinases Over-Signaling 368
Crizotinib-Resistant NPM-ALK Mutants Confer Differential Sensitivity to Unrelated Alk Inhibitors 342
Synergistic effects of combined Wnt/KRAS inhibition in colorectal cancer cells 313
In Vitro and in Vivo Characterization of Bosutinib as Substrate of the Pglycoprotein Efflux Transporter 312
Reversal of microRNA-150 silencing disadvantages crizotinib-resistant NPM-ALK(+) cell growth 310
Crizotinib in advanced, chemoresistant anaplastic lymphoma kinase-positive lymphoma patients 309
Synergistic drug combinations prevent resistance in ALK+ anaplastic large cell lymphoma 298
Colorectal tumors are effectively eradicated by combined inhibition of {beta}-catenin, KRAS, and the oncogenic transcription factor ITF2 290
Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK 286
Abstract 3583: Drug-resistant NPM/ALK mutants show different sensitivity to second generation tyrosine kinase inhibitors 279
NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922 272
Abstract 2920: Excess of cytoplasmic NPM-ALK driven oncogenic signaling is toxic and promotes cellular apoptosis and drug dependency 266
Crizotinib-resistan NPM-ALK mutants confer differential sensitivity to unrelated alk inhibitors 262
Whole exome sequencing reveals NOTCH1 mutations in anaplastic large cell lymphoma and points to Notch both as a key pathway and a potential therapeutic target 259
Discovery of Novel α-Carboline Inhibitors of the Anaplastic Lymphoma Kinase 246
Synergistic Activity of ALK and mTOR Inhibitors for the Treatment of NPM-ALK Positive Lymphoma 245
Resistance Profile of the BCR/ABL Inhibitor Bosutinib Using a High Throughput random Mutagenesis Assay 231
Erratum: Treatment efficacy and resistance mechanisms using the second-generation ALK inhibitor AP26113 in human NPM-ALK-positive anaplastic large cell lymphoma (Molecular Cancer Research (2015) 13 (775-783)) 226
Identification of non-ATP-competitive α-carboline inhibitors of the anaplastic lymphoma kinase 218
Synergistic drug combinations preventdrug resistance in anaplastic large cell lymphomapreclinical models 211
Mechanisms of resistance to the second-generation ALK inhibitor AP26113 in human NPM-ALK-positive anaplastic large cell lymphoma cells 178
Totale 9.277
Salva come PNG Salva come JPEG
Categoria #
all - tutte 29.604
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 29.604
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022256 0 0 0 0 30 40 20 25 18 39 32 52
2022/2023849 83 244 88 88 60 114 8 58 52 20 19 15
2023/2024523 16 18 24 25 58 169 101 12 36 9 2 53
2024/20251.115 67 114 57 54 100 42 75 31 134 181 90 170
2025/20263.095 362 137 226 384 386 150 426 118 263 262 199 182
2026/2027926 93 144 272 390 27 0 0 0 0 0 0 0
Totale 9.277